.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,070,808

« Back to Dashboard

Claims for Patent: 7,070,808

Title:Adhesive mixture for transdermal delivery of highly plasticizing drugs
Abstract:Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
Inventor(s): Govil; Sharad K. (Essex, VT), Weimann; Ludwig J. (Burlington, VT)
Assignee: Mylan Technologies, Inc. (St. Albans, VT)
Application Number:09/754,909
Patent Claims: 1. A therapeutic adhesive formulation comprising: between about 65% and about 97%, by weight, of an acrylic polymeric adhesive which includes between about 40% and about 90% of a C.sub.4 C.sub.12 alkyl acrylate, between about 10% and about 40% by weight of a C.sub.1 C.sub.4 alkyl acrylare hardening monomer; between about 1% and about 20% by weight of a monomer which provides functional groups for crosslinking; and a crosslinking agent; and between about 3% and about 35% by weight, based on the weight of said mixture, of a highly plasticizing drug.

2. The therapeutic adhesive formulation of claim 1 wherein said C.sub.4 C.sub.12 alkyl acrylare is selected from the group consisting of 2-ethylhexyl acrylate, butyl acrylate, n-decyl, n-nonyl, 2 ethyoctyl, isooctyl and dodecyl-acrylate.

3. The therapeutic adhesive formulation of claim 1 wherein said C.sub.4 C.sub.12 alkyl acrylate is provided in an amount of between about 60% and about 80% by weight based on the weight of the adhesive.

4. The therapeutic adhesive formulation of claim 2 wherein said C.sub.1 C.sub.4 alkyl acrylate hardening monomer is selected from the group consisting of methyl acrylate, methyl methacrylate, ethylacrylate, ethyl methacrylate, hydroxyethyl acrylate and hydroxy propyl methacrylate.

5. The therapeutic adhesive formulation of claim 1 wherein said C.sub.1 C.sub.4 alkyl acrylate hardening monomer is provided in an amount of between about 15% and about 30% by weight based on the weight of the adhesive.

6. The therapeutic adhesive formulation of claim 1 wherein said functionalizing monomer which facilitates crosslinking is selected from the group consisting of acrylic acid, hydroxy ethylacrylate, methacrylic acid and acrylamide.

7. The therapeutic adhesive formulation of claim 1 wherein said functionalizing monomer which facilitates crosslinking is provided in an amount of between about 3% and about 8% by weight based on the weight of the adhesive.

8. The therapeutic adhesive formulation of claim 1 wherein said highly plasticizing drug is selected from the group consisting of selegiline, fluoxetine, Des-methyl selegiline, tetracaine and chlorpheniramine.

9. The therapeutic adhesive formulation of claim 8 wherein said highly plasticizing drug is selegiline.

10. The therapeutic adhesive formulation of claim 1 wherein said highly plasticizing drug is provided in an amount of between about 3% and about 25% by weight of the finished adhesive& and drug mixture.

11. The therapeutic adhesive formulation of claim 10 wherein said highly plasticizing drug is provided in an amount of between about 3% and about 18% by weight of the finished adhesive and drug mixture.

12. The therapeutic adhesive formulation of claim 11 wherein said crosslinking agent is selected from the group consisting of butyl titinate, polybutyl titinate, aluminum isopropoxide, butyl titinate, aluminum zinc acetate, multivalent metals, methylol ureas and melamines.

13. The therapeutic adhesive formulation of claim 12 wherein said crosslinking agent is provided in an amount of between about 0.005% and about 2.0% based on the weight of the adhesive.

14. The therapeutic adhesive formulation of claim 1 wherein said formulation is anhydrous and substantially free of volatile solvents after drying.

15. A drug containing and releasing adhesive mixture comprising: between about 65% and about 97%, by weight of an acrylic polymeric adhesive which includes between about 60% and about 80% of a C.sub.4 C.sub.12 alkyl acrylate selected from the group consisting of 2-ethylhexyl acrylate, butyl acrylate, n-decyl, n-nonyl, 2 ethyoctyl, isooctyl and dodecyl-acrylate; between about 15% and about 30% by weight of a C.sub.1 C.sub.4 alkyl acrylate hardening monomer selected front the group consisting of methyl acrylate, methyl methacrylate, ethylacrylate, ethyl methacrylate, hydroxyethyl acrylate and hydroxy propyl methacrylate; between about 1% and about 20% by weight of a functionalizing monomer which facilitates crosslinking selected from the group consisting of acrylic acid, hydroxy ethylacrylate, methacrylic acid and acrylamide; and a crosslinking agent provided in an amount of between about 0.005% and about 2.0%; and between about 3% and about 35% by weight, based on the weight of said mixture, of a highly plasticizing drug selected from the group consisting of selegiline, fluoxetine, des-methyl selegiline, tetracaine and chlorpheniramine.

16. The therapeutic adhesive formulation of claim 15 wherein said highly plasticizing drug is selegiline.

17. The therapeutic adhesive formulation of claim 15 which does not include a solvent after drying.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc